EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.
EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned in 2020.
EpiEndo is an international virtual company coordinated by an experienced team.